Latest

Super Micro Computer: Why It's Still Worth Having In Your Portfolio (Archive)

SMCI combines robust backlog growth, moderated valuations, and technicals that still favor outperformance.

XPLR Infrastructure: Sell Now If You Haven't Already (Archive)

XPLR slashes payouts, pivots to self-funded growth, but remains a bearish transition story.

ASML: Why It's Too Early To Buy (Archive)

ASML’s growth hinges on services as weakening system demand and bookings temper upside.

Nvidia: Not Yet A Buy, Here's What To Wait For (Archive)

Waiting for a deeper pullback before loading up on Nvidia's next growth leg.

Enovix: A Worthy Buy For Asymmetric Upside (Archive)

Enovix offers asymmetric upside as commercialization lags but customer, manufacturing, and R&D milestones advance.

Devon Energy: Stay Away From This Value Trap (Archive)

Limited growth, mixed commodity outlook, and murky technicals make DVN a likely value trap.

CVS Health: One Good Quarter Is Not Enough; Retain Sell (Archive)

CVS' rally masks persistent insurance margin pressures, rich valuation, and rising leverage risks.